NewsRoom Articles - Page 110 of 154 - PsychedelicNewsWire (PNW)

ThursdayJan 07, 2021 11:25 am

Functional Mushroom Market Set to Grow in Coming Years

In 2020, functional mushrooms successfully transitioned from the wellness pipeline into the mainstream market, with more opportunities set to open up as many anticipate extensive psychedelic legalization. Oregon legalizing the use of psilocybin mushrooms, a psychedelic, for therapeutic use and the potential and health benefits of these mushrooms are good signs. People looking to consume adaptogens can find mushrooms in literally anything, including jerky, supplements, tea and coffee as well as beauty products. The functional mushroom market on a global scale was valued at $23 billion last year. The forecasted compound yearly growth rate is said to be 5.6% over…

WednesdayJan 06, 2021 2:15 pm

2020: A Bad Year for the Global Economy, a Good Year for the Psychedelics Industry

Last year was a good year for many psychedelic companies and psychedelics in general, as they went mainstream, with many substances being studied for the potential to treat various mental health conditions. Various psychedelic companies — those dealing with production as well as research — moved into investment markets, with roughly 24 companies going public between February and December 2020. The first among these was Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF), which became the first psychedelics firm to debut an IPO in Canada, launching March 3 on the NEO exchange. Canada’s conducive environment for small-cap venture investment set up…

WednesdayJan 06, 2021 1:59 pm

Pure Extracts Technologies (CSE: PULL) Draws Out Expansion Plans in Anticipation of Regulatory Changes Within Mushroom Sector

Pure Extracts Technologies Corp. has announced plans to expand, build fourth unit in dedicated towards research, development of psilocybin Announcement on its expansion plans come shortly after the Company revealed it plans to apply to Health Canada for a Dealer’s License Award of Dealer’s License would allow Pure Extracts to cultivate, harvest and procure controlled substances and carry out research into psychedelic compounds such as psilocybin and psilocin – paving way towards future commercialization of its product The Dealer’s License application has taken on increased relevance following Health Canada’s decision to revise existing regulations to permit certain authorized uses of…

TuesdayJan 05, 2021 1:01 pm

Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin

U.S. taking actionable steps toward acceptance of psilocybin States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of psychedelic products. The company's subsidiary Serenity Life Sciences is focused on the research and development of psilocybin-based medications. Psilocybin, referred to by the media as magic mushrooms, has had its share of bad press. The stigma of this substance has halted R&D in America in…

TuesdayJan 05, 2021 9:30 am

Research Suggests That Single Dose of Psychedelics May Alleviate Racial Injustice Trauma

A recent study has suggested that one positive experience on a psychedelic medicine may help alleviate anxiety, depression and stress symptoms in Indigenous and Black people as well as people of color who have been affected by racism. The retrospective study involved 30 participants who admitted that in the 30 days following an experience with either ecstasy (“MDMA”), psilocybin mushrooms or LSD, the trauma-related symptoms they experienced that were connected with acts of racism were reduced. Ohio State University assistant professor of social work Alan Davis, who was also a co-lead author of the study, explained that the participants’ experience…

MondayJan 04, 2021 1:15 pm

VC Fund Committed to Psychedelic Medicine Development Launched in UK

In the past couple of years, biopharmaceutical firms focused on psychedelic medicines have increased in number. Two weeks ago, UK’s first psychedelic investment fund was launched. The fund is committed to psychedelic health care and hopes to invest in psychedelic medicines to treat conditions such as anxiety, addiction and depression. The fund was established by VC Neo Kuma Ventures, an organization based in London, which was formed by Nick David, Clara Burtenshaw and Sean McLintock in 2019. In the same year, the founders of Neo Kuma gave their support to ATAI Life Sciences AG, the co-owner of COMPASS Pathways (NASDAQ:…

ThursdayDec 31, 2020 12:25 pm

Shrooms Vs. LSD: Are They the Same?

During the general elections held in November 2020, Oregon voters made history by passing Measure 110 and Measure 109. The former decriminalizes the possession of small amounts of all illicit substances while the latter allows adult use of psilocybin mushrooms in a therapeutic setting. Psychedelics are made up of various substances including LSD, commonly known as acid, and “magic” mushrooms, or psilocybin mushrooms. While there are some similarities between both LSD and mushrooms, both may elicit experiences that differ in individuals. Psilocybin is a psychedelic component found in the mushroom species Psilocybe cubensis. On the other hand, LSD’s origin was…

ThursdayDec 31, 2020 12:08 pm

Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy

Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD Newly discoverable data from psychedelic studies may potentially create entirely new marketplace of safe and effective drugs Cybin (NEO: CYBN), a mushroom life sciences company, is working to become the first to bring a psilocybin drug to market targeting major depressive disorder (“MDD”). According to the National Institute of Mental Health, more than 18 million people in the United States — and 300 million people worldwide — experience major depression.…

WednesdayDec 30, 2020 9:45 am

New Hampshire Supreme Court Supports Freedom for Psychedelic Use in Religious Ceremonies

Last week, the Supreme Court of New Hampshire overturned an earlier conviction of a resident from the North Country, whose charges of psilocybin mushroom possession were filed in 2018. The court ruled that the earlier conviction conflicted with the religion the defendant practices, which is Native American based. The sitting justices stated in a unanimous ruling that as compared to protections in the U.S. constitution, the right of religion in the New Hampshire constitution was stronger. Under the U.S. constitution, sterner balancing tests are required in the event that the illegal drugs in question are used for religious practices. The…

TuesdayDec 29, 2020 10:45 am

Psychedelic Medicines May Develop into $100 Billion Business Opportunity

Psychedelic drugs have shown a lot of potential with regard to managing various mental health conditions. Canaccord Genuity Capital Markets analyst Tania Gonsalves states that more investors are getting into the psychedelic space, which may be worth nearly $100 billion. The psychedelic space is also becoming more mainstream as more and more cities decriminalize psychedelics such as psilocybin. Santa Cruz, Denver and Oakland legalized psilocybin use with the state of Oregon becoming the first state in the United States to legalize the use of psilocybin in a therapeutic setting. Top psychedelic firms to watch include New Wave Holdings Corp. (CSE:…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000